comparemela.com

Latest Breaking News On - Salarius pharmaceuticals - Page 26 : comparemela.com

Spinal Muscular Atrophy (SMA) Treatment Market 2020 to Showing Impressive Growth by 2027 | Industry Trends, Share, Size, Top Key Players Analysis and COVID-19 Impact Analysis 2027 – KSU

ADVAXIS INC (ADXS), AEterna Zentaris Inc (NASDAQ:AEZS) - 12 Health Care Stocks Moving In Friday s After-Market Session

ADVAXIS INC (ADXS), AEterna Zentaris Inc (NASDAQ:AEZS) - 12 Health Care Stocks Moving In Friday s After-Market Session
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Salarius Pharmaceuticals Announces Dr Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference

During the event, Dr. Santiesteban and other panel members will discuss the current status of targeted cancer therapies, as well as the future outlook for research and drug development in the field. Salarius is developing seclidemstat, a reversible LSD1 inhibitor that is now being studied in two clinical trials one trial in relapsed/refractory Ewing sarcoma, a rare and deadly pediatric bone and soft tissue cancer, and a second trial in advanced solid tumors (AST). Salarius expects to establish maximum tolerated dose (MTD) in its Ewing sarcoma trial and advance into the dose-expansion phase of the Ewing sarcoma trial in early 2021. Salarius also expects to expand the same trial to include additional select sarcomas that share a similar biology to Ewing sarcoma, also known as Ewing-related sarcomas.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.